Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device [Yahoo! Finance]
Femasys Inc. (FEMY)
Company Research
Source: Yahoo! Finance
The device offers controlled delivery of contrast, confirming tubal status safely and efficiently. Femasys has achieved U.S. FDA clearance and Canadian regulatory approval for FemChec, a diagnostic solution designed for the controlled delivery of natural contrast during ultrasound evaluations of fallopian tubes. The device uses an alternating saline and air pattern to assist in confirming tubal status. FemChec plays a key role in Femasys' ongoing pivotal trial for FemBloc, its non-surgical permanent birth control solution, where it is used to confirm the procedure's success. Shares of FEMY closed 1.9% higher on Sept. 9 following the news. Significance of FDA's Clearance for Femasys' FemChec The FDA clearance of FemChec reinforces the company's commitment to advancing women's health diagnostics. It eliminates the need for X-rays and radiology referrals, providing a radiation-free, in-office alternative for tubal assessments. FemChec is also crucial for the FemBloc non-surgical
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic DevicesGlobeNewswire
- Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices [Yahoo! Finance]Yahoo! Finance
- Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic DevicesGlobeNewswire
- Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control [Yahoo! Finance]Yahoo! Finance
FEMY
Sec Filings
- 1/30/25 - Form 4
- 1/30/25 - Form 4
- 1/30/25 - Form 4
- FEMY's page on the SEC website